clinical trial · NCT05936281
A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
Changchun GeneScience Pharmaceutical Co., Ltd.·phase2·completed·n = 165
GoutGout Initiating Urate-loweringUrate-lowering TherapyGenakumab for injectionColchicine
brief summary
To evaluate the safety and efficacy of Genakumab in prevention of acute flares in gout patients initiating urate-lowering therapyurate-lowering
started
Jul 20, 2023
primary completion
Jan 19, 2024
completion
Jan 19, 2024
last updated
Jan 1, 2025
detailed description
A randomized, open-lable, multi-center, active-controlled Phase 2 study. Patients are randomized to Genakumab 100mg single injection group, Genakumab 200mg single injection group or oral colchicine 0.5mg once a day.for 12 weeks group.
official title
A Randomized, Open-lable, Multi-center, Active-controlled Phase 2 Study for Evaluating Efficacy and Safety of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol